Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Opioids

Alzheimer’s drug reduces illicit opioid use in methadone recipients

Self-reported days of abstinence from illicit opioids were significantly higher in the galantamine group than in the placebo group during the study period, at 92.5% compared with 86.3%.

People who take methadone use fewer illicit opioids when galantamine is added to their therapy, research shows[1].

The study, published in the American Journal on Addictions (4 June 2019), was a secondary analysis of trial data in which 120 methadone-maintained people with concurrent cocaine dependence were randomly assigned to galantamine or placebo for 12 weeks.

The researchers found that urine samples were negative for opioids in 76.7% of samples from the treatment group and 62.4% in the placebo group, and these effects persisted into the six-month follow-up. Self-reported days of abstinence from illicit opioids were significantly higher in the galantamine group than in the placebo group during the study period, at 92.5% compared with 86.3%. 

Also, the time to first opioid use was significantly longer in the galantamine group, at a median of 52.5 days compared with 14.5 days in the placebo group.

Galantamine is a cholinesterase inhibitor used in Alzheimer’s disease to improve cognitive and emotional function, and research has suggested that it is beneficial in cigarette and alcohol addiction.

The original trial published in 2018 in the Journal of Clinical Psychology tested whether galantamine enhanced the effect of computerised cognitive behavioural therapy in people with cocaine addiction.

“If these results are supported in future trials, galantamine may hold promise across multiple drugs of abuse, including opioids,” the researchers concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206805

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.